摘要
Abstract
Objective:To explore the clinical effect of Anlotinib combined with concomitant radiochemotherapy(CCRT)in the treatment of locally advanced esophageal squamous cell carcinoma.Method:Clinical data of 80 patients with locally advanced esophageal squamous cell carcinoma treated in Liaocheng Infectious Disease Hospital from June 1,2021 to June 1,2022 were retrospectively analyzed,and divided into control group(n=38)and observation group(n=42)according to treatment regimen.The control group was treated with CCRT,and the observation group was treated with CCRT combined with Anlotinib.Progression free survival(PFS),overall survival(OS),disease control rate(DCR),objective response rate(ORR)and adverse events(AE)of the two groups were evaluated.Result:The ORR and DCR of observation group were 69.05%and 90.48%,respectively,which were significantly higher than 47.39%and 63.16%of control group,the differences were statistically significant(P<0.05).The median OS was 16 months[95%CI(14.484,17.516)]in the control group and 20 months[95%CI(15.585,24.415)]in the observation group,the difference between the two groups was statistically significant(x2=7.341,P=0.007).The median PFS was 15 months[95%CI(9.523,20.477)]in the control group and 20 months[95%CI(15.581,24.419)]in the observation group,the difference between the two groups was statistically significant(x2=12.844,P<0.001).There were no significant differences in the incidence of leucocytopenia,thrombocytopenia,anemia,gastrointestinal reaction,radiation esophagitis and cutaneous reaction between the two groups(P>0.05).The incidence of Ⅰ and Ⅱ grade hypertensive in observation group was significantly higher than that in control group(P<0.05).Conclusion:Anlotinib combined with CCRT in the treatment of locally advanced esophageal squamous cell carcinoma can improve the clinical efficacy,and prolong the survival time of patients.关键词
安罗替尼/同步放化疗/食管鳞状细胞癌/无进展生存期/总生存期Key words
Anlotinib/Concomitant radiochemotherapy/Esophageal squamous cell carcinoma/Progression free survival/Overall survival
